Listen on the go
CORRECT!
Next question
touchHAEMATOLOGY touchHAEMATOLOGY

Start Learning

Touch Loading image
touchCONGRESS
Start Learning
Optimizing treatment of CML in the first-line setting and beyond: Insights from EHA 2024 and ESH-iCMLf 2024
touchCONGRESS
Start Learning
Insights from EHA and ISTH 2024: How can we optimize care for patients with chronic ITP?
CE/CME ACCREDITED
touchPANEL DISCUSSION
Start Learning
Multidisciplinary insights: Navigating the challenges of systemic mastocytosis diagnosis and management
CE/CME ACCREDITED
CONFERENCE HUB
Start Learning
Empowering young haematologists: Insights from the EBMT Trainee Committee co-chairs
CONFERENCE HUB
Start Learning
Supporting young haematologists: Insights on YoungEHA and EHA 24
CONFERENCE HUB
Start Learning
Durable clinical benefit with elritercept in lower-risk MDS: KER050-MD-201 trial
CONFERENCE HUB
Start Learning
Potential of elritercept (KER-050) to treat myelofibrosis: RESTORE trial
CONFERENCE HUB
Start Learning
Is there an alternative to intensive chemotherapy for patients with acute myeloid leukemia? Key insights from ASH 2024
Madrid
JOURNALS
Start Learning
EHA 2024: Highlights of the late-breaking abstracts
San-Diego
JOURNALS
Start Learning
#ASH24: The countdown is on!

to view Favourites, Keep Notes and Track CME Credits

Favourites
Tailoring treatment in myelofibrosis: Addressing anaemia and thrombocytopenia
View
Supporting young haematologists: Insights on YoungEHA and EHA 24
View
#ASH24: The countdown is on!
View
Advancing care in myelodysplastic syndromes: Expert insights from Prof. Pierre Fenaux
View
Supporting haematology patient care: Insights from the Haematology Nurses and Healthcare Professionals Group
View
Combination therapy in myelofibrosis: John Mascarenhas on the IMpactMF trial
View
Is there an alternative to intensive chemotherapy for patients with acute myeloid leukemia? Key insights from ASH 2024
View
Key highlights from ASH 2024: Promising new therapies for relapsed/refractory acute myeloid leukaemia
View
#ASH24: Must-know updates in multiple myeloma
View
Isatuximab demonstrated consistent PFS benefits across diverse patient profiles in RRMM in 2 pivotal trials
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup